| HOME >> BIOLOGY >> TECHNOLOGY |
HUNTINGTON BEACH, California, and AMSTERDAM, The Netherlands, March 11 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that leading researchers from Agendia and the Netherlands Cancer Institute will present data from multiple studies at the 2009 St.Gallen Breast Cancer Conference. The St. Gallen Breast Cancer Conference, one of the premiere conferences in breast cancer research worldwide, takes place March 11th-14th, 2009 in St.Gallen, Switzerland.
The study results further underpin the predictive and prognostic power of Agendia's breast cancer recurrence test, MammaPrint(R) and will be discussed at the following poster sessions:
Thursday, 12 March 2009
Poster 0063
Comparison of MammaPrint and TargetPrint Results with Clinical Parameters in German Patients (PATH) with Early Stage Breast Cancer
G. Kunz, T. Dimpfl, C. Jakisch, R. Buttner, F. A. de Snoo, O. Krijgsman, E. van Lienen, A. Glas, and R. Bender.
Thursday, 12 March 2009
Poster 0071
The 70 Gene-MammaPrint Profile Allows to Identify a Subgroup of Good-Prognostic Patients with Primary Breast Cancer and 4-9 Positive Lymph Nodes
M. Saghatchian, S. Mook, G. Pruneri, G. Viale, A. Glas, I. Eekhout, M. Knauer, and LJ van 't Veer.
Thursday, 12 March 2009
Poster 0072
The 70-gene MammaPrint Prognosis Signature for Optimal Risk Stratification in Endocrine Responsive Breast Cancer
M Knauer, EJT Rutgers, S Mook, F Cardoso, MJ van de Vijver, G Viale, AM Glas, M. Saghatchian, M Kok, JM Bueno-de-Mesquita, SC Linn and LJ van 't Veer.
Thursday, 12 March 2009
Poster 0073
The 70-gene MammaPrint Signature Is Predictive for Chemotherapy Benefit in Early Breast Cancer
M Knauer, ME Sraver, EJT Rutgers, RA Bender, F Cardoso, S Mook, MJ
'/>"/>
| SOURCE Agendia B.V. Copyright©2009 PR Newswire. All rights reserved |